Dhabi, UAE, May 13, 2023 (GLOBE NEWSWIRE) — According to a comprehensive research report by Market Research Future…
Source: www.globenewswire.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
